吳 俊欣

Medicine & Life Sciences

1. Cohort Studies 96%
2. Pulmonary Arterial Hypertension 95%
3. Systemic Lupus Erythematosus 75%
4. Polymyositis 54%
5. Chronic Kidney Failure 53%
6. Dermatomyositis 49%
7. Myositis 49%
8. Connective Tissue Diseases 48%
9. Systemic Scleroderma 46%
10. Mycobacterium 43%
11. Metformin 43%
12. Mortality 42%
13. Autoimmune Diseases 41%
14. Myocardial Ischemia 35%
15. Arthritis 35%
16. Tuberculosis 33%
17. Immune System 32%
18. Incidence 30%
19. Parents 30%
20. Inflammation 29%
21. Observation 28%
22. Kidney 28%
23. Joints 28%
24. Confidence Intervals 28%
25. Survival 22%
26. Antibodies 22%
27. Propensity Score 21%
28. Chronic Renal Insufficiency 18%
29. Proportional Hazards Models 16%
30. Control Groups 15%
31. Databases 14%
32. Reactive Oxygen Species 13%
33. Population Control 12%
34. Population 11%
35. Infections 11%
36. Anti-Inflammatory Agents 10%
37. Comorbidity 9%
38. Survival Rate 9%
39. Familial Primary Pulmonary Hypertension 8%
40. Oxidation-Reduction 8%
41. Diabetes Mellitus 8%
42. Brain Natriuretic Peptide 7%
43. Patient Rights 7%